Stomatological Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences, Chongqing, China.
Drug Deliv. 2021 Dec;28(1):620-633. doi: 10.1080/10717544.2021.1902020.
Minocycline hydrochloride (MINO) has been one of the most frequently used antibiotics in the treatment of periodontitis due to its antibacterial activity and osteogenesis effects; however, high levels of MINO administered during the treatment halt the formation of new bone. Therefore, the purpose of the present study was to prepare a MINO-microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot to reduce the burst release of MINO and ensure antibacterial and osteogenesis effects of MINO in the treatment of periodontitis. Uniform microspheres, approximately 5 µm size, with a slightly rough surface and different MINO loading (10, 12, and 14%) were prepared, and the microspheres were added into SAIB, after which the burst release significantly decreased from 66.18 to 2.92%, from 71.82 to 3.82%, and from 73.35 to 4.45%, respectively, and the release from all the MINO-microspheres/SAIB hybrid depots lasted for 77 days. In addition, cytotoxicity test showed that the MINO-microsphere with 12% drug loading promoted the proliferation of osteoblasts the most and was subsequently used in vivo experiments. Moreover, in the model of ligatured-induced periodontitis in SD rats, the MINO-microsphere/SAIB hybrid depot not only significantly increased the alveolar bone height and bone volume but also reduced the inflammation of the periodontal tissue. Additionally, it also inhibited the expression of the receptor activator of nuclear factor-kappa B ligand (RANKL) and promoted the expression of osteoprotegerin (OPG).. These results indicated that the MINO-microsphere/SAIB hybrid depot might be promising in the treatment of periodontitis.
盐酸米诺环素(MINO)因其具有抗菌活性和成骨作用,已成为治疗牙周炎最常用的抗生素之一;然而,治疗过程中给予的高浓度 MINO 会阻止新骨形成。因此,本研究旨在制备 MINO-微球/醋酸异丁酸蔗糖酯(SAIB)混合储库,以减少 MINO 的爆发释放,并确保 MINO 在治疗牙周炎中的抗菌和成骨作用。制备了粒径约为 5 µm、表面略粗糙且 MINO 载药量(10%、12%和 14%)不同的均匀微球,将微球加入到 SAIB 中后,突释明显从 66.18%降至 2.92%、71.82%降至 3.82%和 73.35%降至 4.45%,所有 MINO-微球/SAIB 混合储库的释放持续了 77 天。此外,细胞毒性试验表明,载药量为 12%的 MINO 微球对成骨细胞的增殖促进作用最大,随后用于体内实验。此外,在 SD 大鼠结扎诱导牙周炎模型中,MINO-微球/SAIB 混合储库不仅显著增加了牙槽骨高度和骨量,还减轻了牙周组织的炎症。此外,它还抑制了核因子-κB 受体激活剂配体(RANKL)的表达,促进了骨保护素(OPG)的表达。这些结果表明,MINO-微球/SAIB 混合储库可能在治疗牙周炎方面具有广阔的应用前景。